Additionally, the 36-month beta value for IMNM is 1.92. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMNM is 52.86M and currently, short sellers hold a 19.95% ratio of that float. The average trading volume of IMNM on February 04, 2025 was 956.36K shares.
IMNM) stock’s latest price update
The stock price of Immunome Inc (NASDAQ: IMNM) has jumped by 4.94 compared to previous close of 10.32. Despite this, the company has seen a gain of 17.21% in its stock price over the last five trading days. businesswire.com reported 2025-01-31 that BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, befo.
IMNM’s Market Performance
IMNM’s stock has risen by 17.21% in the past week, with a monthly rise of 2.85% and a quarterly drop of -5.58%. The volatility ratio for the week is 8.35% while the volatility levels for the last 30 days are 7.63% for Immunome Inc The simple moving average for the past 20 days is 6.11% for IMNM’s stock, with a -17.69% simple moving average for the past 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Stephens repeating the rating for IMNM by listing it as a “Overweight.” The predicted price for IMNM in the upcoming period, according to Stephens is $30 based on the research report published on November 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $27. The rating they have provided for IMNM stocks is “Overweight” according to the report published on May 31st, 2024.
JP Morgan gave a rating of “Overweight” to IMNM, setting the target price at $24 in the report published on April 30th of the previous year.
IMNM Trading at -3.66% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.02% of loss for the given period.
Volatility was left at 7.63%, however, over the last 30 days, the volatility rate increased by 8.35%, as shares sank -3.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.23% upper at present.
During the last 5 trading sessions, IMNM rose by +17.10%, which changed the moving average for the period of 200-days by -37.74% in comparison to the 20-day moving average, which settled at $10.21. In addition, Immunome Inc saw 1.98% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from SIEGALL CLAY B, who purchase 150,000 shares at the price of $7.75 back on Jan 31 ’25. After this action, SIEGALL CLAY B now owns 669,636 shares of Immunome Inc, valued at $1,162,500 using the latest closing price.
SIEGALL CLAY B, the President and CEO of Immunome Inc, purchase 66,057 shares at $9.54 during a trade that took place back on Nov 21 ’24, which means that SIEGALL CLAY B is holding 485,693 shares at $630,263 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.88 for the gross margin
The net margin for Immunome Inc stands at -30.15. The total capital return value is set at -1.46. Equity return is now at value -276.36, with -174.46 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -31.68. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1579.52.
Currently, EBITDA for the company is -28.27 million with net debt to EBITDA at 1.36. When we switch over and look at the enterprise to sales, we see a ratio of 52.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.17.
Conclusion
In conclusion, Immunome Inc (IMNM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
